[
  {
    "ts": null,
    "headline": "DexCom’s Q4 Beat And 2026 Targets Tested By Rising CGM Competition",
    "summary": "DexCom reported strong preliminary Q4 results, with topline figures above its earlier expectations. The company paired this update with a positive outlook for 2026, outlining targets that support its longer term growth plans. These announcements come as competition in glucose monitoring intensifies and recent analyst views on NasdaqGS:DXCM have turned more mixed. DexCom, traded as NasdaqGS:DXCM, last closed at $73.04. The stock is up 9.8% over the past month and 9.8% year to date, but it...",
    "url": "https://finnhub.io/api/news?id=d06370b56802b132308c385ae805a4364dcb1af929113ae4fc77cff70391f23c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769926066,
      "headline": "DexCom’s Q4 Beat And 2026 Targets Tested By Rising CGM Competition",
      "id": 138322087,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "DexCom reported strong preliminary Q4 results, with topline figures above its earlier expectations. The company paired this update with a positive outlook for 2026, outlining targets that support its longer term growth plans. These announcements come as competition in glucose monitoring intensifies and recent analyst views on NasdaqGS:DXCM have turned more mixed. DexCom, traded as NasdaqGS:DXCM, last closed at $73.04. The stock is up 9.8% over the past month and 9.8% year to date, but it...",
      "url": "https://finnhub.io/api/news?id=d06370b56802b132308c385ae805a4364dcb1af929113ae4fc77cff70391f23c"
    }
  },
  {
    "ts": null,
    "headline": "What DexCom (DXCM)'s Strong Q4 Beat and 2026 Margin Guidance Means For Shareholders",
    "summary": "DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and international markets, beating consensus expectations and pairing this with guidance for higher 2026 revenue and improved adjusted margins. This stronger operational outlook has prompted many analysts to reiterate positive ratings even as some highlight rising competition in DexCom’s core insulin-intensive segments. Next, we’ll examine how DexCom’s upbeat 2026 guidance for...",
    "url": "https://finnhub.io/api/news?id=875702521aad2d4b259e47e9cc3e761c6a3a36c2358e537115264673e352735e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769911775,
      "headline": "What DexCom (DXCM)'s Strong Q4 Beat and 2026 Margin Guidance Means For Shareholders",
      "id": 138321150,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and international markets, beating consensus expectations and pairing this with guidance for higher 2026 revenue and improved adjusted margins. This stronger operational outlook has prompted many analysts to reiterate positive ratings even as some highlight rising competition in DexCom’s core insulin-intensive segments. Next, we’ll examine how DexCom’s upbeat 2026 guidance for...",
      "url": "https://finnhub.io/api/news?id=875702521aad2d4b259e47e9cc3e761c6a3a36c2358e537115264673e352735e"
    }
  }
]